Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00289861 · ClinicalTrials.gov registry record · Phase 4
Risperidone Augmentation in Patients With Schizophrenia
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT00289861: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00289861 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00289861, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
We propose a double-blind, placebo-controlled trial to study the effectiveness and tolerability of adding risperidone to stable yet only partially remitted patients with schizophrenia maintained on clozapine.
Interventions
- DRUG placebo
- DRUG Risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-02 |
| Est. Completion | 2007-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00289861
The ClinicalTrials.gov registry entry for NCT00289861 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00289861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00289861 about?
NCT00289861 is a clinical study titled "Risperidone Augmentation in Patients With Schizophrenia". We propose a double-blind, placebo-controlled trial to study the effectiveness and tolerability of adding risperidone to stable yet only partially remitted patients with schizophrenia maintained on clozapine.
What is the current status of trial NCT00289861?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2003-02. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00289861?
The interventions under investigation include: placebo (DRUG), Risperidone (DRUG).
Who is sponsoring clinical trial NCT00289861?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.